Medical Science Liaison (North Central Plains)
ArcellxFull Time
Senior (5 to 8 years), Expert & Leadership (9+ years)
Candidates must possess an advanced scientific or medical degree (PhD, PharmD, MD, MSN, BSN), a fundamental understanding of molecular oncology and related patient management algorithms, and existing KOL relationships in oncology. A working knowledge of genomic laboratory-developed testing (LDT), familiarity with CLIA-88’, CAP, and Sunshine Act (2013), public speaking skills, exceptional interpersonal communication skills, strong inter- and intradepartmental management skills, and the ability to educate and train are also required. A basic understanding of oncology is necessary, with a strong preference for a basic understanding of molecular testing. Prior MSL experience in diagnostics, biotech, or pharmaceutical industries is preferred, and the ability to travel up to 50% is essential.
The Medical Science Liaison will act as a sales and commercial team support, serving as a regional expert on Tempus oncology assays to promote scientific information exchange with regional KOLs and other oncology physicians. They will facilitate education for healthcare providers through in-person or virtual presentations, proactively and reactively communicating scientific data. Responsibilities also include providing scientific education for internal stakeholders, attending conferences to provide meeting synopses and summaries of high-impact scientific content, and continuously updating internal teams on relevant medical and scientific knowledge while sharing market intelligence.
AI-driven healthcare data analysis platform
Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in healthcare. The company offers a platform that analyzes medical data to provide insights for physicians, helping them make better treatment decisions. This platform also aids pharmaceutical and biotech companies in drug development by identifying new targets and assessing treatment effectiveness. For patients, Tempus identifies personalized therapy options, particularly in cancer care, where their research has shown increased opportunities for tailored treatments. They have developed a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. Tempus generates revenue by charging healthcare providers and companies for access to their platform and insights, setting them apart from competitors by their focus on personalized medicine and extensive cancer research.